• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病增加慢性乙型肝炎患者发生肝细胞癌和死亡的风险:一项基于人群的队列研究。

Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: A population-based cohort study.

机构信息

Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.

Department of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan.

出版信息

J Viral Hepat. 2019 Jun;26(6):718-726. doi: 10.1111/jvh.13077. Epub 2019 Mar 5.

DOI:10.1111/jvh.13077
PMID:30739359
Abstract

Diabetes mellitus may be a risk factor of HCC development in chronic hepatitis B infected patients and affect the all-cause mortality. This study aimed to examine whether DM was associated with the development of HCC with CHB and affected the all-cause mortality. A total of 2966 CHB patients newly diagnosed with DM in 2000 were retrieved from the Longitudinal Cohort of Diabetes Patients database and used propensity scores matching based on age, sex-gender, alcohol-related liver disease and baseline liver cirrhosis to compare with the non-DM patients from the Taiwanese National Health Insurance Research Database. The CHB patients with DM compared to the non-DM had significantly increased (3.3%) risk for HCC development and significantly increased (2.8%) risk of HCC-related mortality. Interestingly, the all-cause mortality was significantly higher in the DM cohort (16.9%) compared to the non-DM cohort (8.2%). In a multivariable transition-specific Cox model to investigate the adjusted hazard ratio of CHB patients with DM or non-DM during the transitions from start to HCC was 1.35; 95% CI (1.16-1.57) and from HCC to death was 1.31; 95% CI (1.06-1.62). All-cause mortality between CHB patients with DM or non-DM during the transitions from start to death was 2.32; 95% CI (1.84-2.92). Taken together, DM is an independent risk factor associated with increasing disease development of HCC, HCC-related mortality and all-cause mortality in CHB patients. This study may provide a clinical strategy for strict DM control in order to reduce the risk of disease development in CHB patients.

摘要

糖尿病可能是慢性乙型肝炎感染患者发生肝癌的一个危险因素,并影响全因死亡率。本研究旨在探讨糖尿病是否与乙型肝炎合并糖尿病患者肝癌的发生有关,并影响全因死亡率。从 2000 年糖尿病患者纵向队列数据库中检索到 2966 例新诊断为糖尿病的乙型肝炎患者,并基于年龄、性别、酒精性肝病和基线肝硬化使用倾向评分匹配,与来自台湾全民健康保险研究数据库的非糖尿病患者进行比较。与非糖尿病患者相比,乙型肝炎合并糖尿病患者发生肝癌的风险显著增加(3.3%),肝癌相关死亡率显著增加(2.8%)。有趣的是,糖尿病组的全因死亡率(16.9%)明显高于非糖尿病组(8.2%)。在多变量特定转移 Cox 模型中,在从起始到肝癌的转变期间,乙型肝炎合并糖尿病或非糖尿病患者的调整后危险比为 1.35;95%CI(1.16-1.57),从肝癌到死亡的调整后危险比为 1.31;95%CI(1.06-1.62)。在从起始到死亡的转变期间,乙型肝炎合并糖尿病或非糖尿病患者的全因死亡率为 2.32;95%CI(1.84-2.92)。综上所述,糖尿病是与乙型肝炎患者肝癌发展、肝癌相关死亡率和全因死亡率增加相关的独立危险因素。本研究可为严格控制糖尿病提供临床策略,以降低乙型肝炎患者疾病发展的风险。

相似文献

1
Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: A population-based cohort study.糖尿病增加慢性乙型肝炎患者发生肝细胞癌和死亡的风险:一项基于人群的队列研究。
J Viral Hepat. 2019 Jun;26(6):718-726. doi: 10.1111/jvh.13077. Epub 2019 Mar 5.
2
Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: A population-based cohort study.糖尿病、肝细胞癌与丙型肝炎感染患者的死亡率:一项基于人群的队列研究。
J Gastroenterol Hepatol. 2017 Jul;32(7):1355-1362. doi: 10.1111/jgh.13670.
3
Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.基于改良 FIB-4 指数对恩替卡韦治疗的慢性乙型肝炎患者进行肝细胞癌风险分层。
J Gastroenterol Hepatol. 2019 Feb;34(2):442-449. doi: 10.1111/jgh.14372. Epub 2018 Jul 19.
4
Association of Metabolic Risk Factors With Risks of Cancer and All-Cause Mortality in Patients With Chronic Hepatitis B.代谢风险因素与慢性乙型肝炎患者癌症和全因死亡率风险的关联。
Hepatology. 2021 Jun;73(6):2266-2277. doi: 10.1002/hep.31612. Epub 2021 Apr 19.
5
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.恩替卡韦与替诺福韦治疗慢性乙型肝炎患者的肝细胞癌风险:一项韩国全国队列研究。
JAMA Oncol. 2019 Jan 1;5(1):30-36. doi: 10.1001/jamaoncol.2018.4070.
6
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.恩替卡韦治疗 4 年可降低慢性乙型肝炎患者的肝细胞癌、肝硬化事件和死亡率。
Liver Int. 2016 Dec;36(12):1755-1764. doi: 10.1111/liv.13253. Epub 2016 Oct 4.
7
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.长期服用恩替卡韦或替诺福韦治疗的慢性乙型肝炎患者的 8 年生存率与一般人群相似。
J Hepatol. 2018 Jun;68(6):1129-1136. doi: 10.1016/j.jhep.2018.01.031. Epub 2018 Feb 8.
8
Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.接受核苷(酸)类似物治疗慢性乙型肝炎的肝硬化患者肝细胞癌的决定因素
J Antimicrob Chemother. 2014 Jul;69(7):1920-7. doi: 10.1093/jac/dku041. Epub 2014 Feb 26.
9
Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.肝硬化而非抗病毒治疗可预测具有不同乙型肝炎病毒状态的队列的临床结局。
Gut Liver. 2019 Mar 15;13(2):197-205. doi: 10.5009/gnl18204.
10
Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.恩替卡韦对乙型肝炎病毒和肝细胞癌的抑制作用。
J Gastroenterol Hepatol. 2011 Sep;26(9):1380-8. doi: 10.1111/j.1440-1746.2011.06776.x.

引用本文的文献

1
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues.代谢综合征疾病对接受核苷(酸)类似物治疗的慢性乙型肝炎患者长期预后的影响。
Clin Mol Hepatol. 2025 Jul;31(3):1003-1017. doi: 10.3350/cmh.2024.1070. Epub 2025 Mar 17.
2
The neutrophil-lymphocyte ratio as a risk factor for all-cause mortality among individuals with resolved HBV infection: evidence from the NHANES 1999-2018.中性粒细胞与淋巴细胞比值作为乙肝病毒感染已治愈个体全因死亡率的危险因素:来自1999 - 2018年美国国家健康与营养检查调查的证据
Front Public Health. 2025 Jan 15;12:1493439. doi: 10.3389/fpubh.2024.1493439. eCollection 2024.
3
Global Burden and Trends of Primary Liver Cancer Attributable to Comorbid Type 2 Diabetes Mellitus Among People Living with Hepatitis B: An Observational Trend Study from 1990 to 2019.
1990年至2019年乙型肝炎感染者中2型糖尿病合并症所致原发性肝癌的全球负担及趋势:一项观察性趋势研究
J Epidemiol Glob Health. 2024 Jun;14(2):398-410. doi: 10.1007/s44197-024-00237-1. Epub 2024 May 7.
4
Type 2 diabetes mellitus characteristics affect hepatocellular carcinoma development in chronic hepatitis B patients with cirrhosis.2型糖尿病特征影响慢性乙型肝炎肝硬化患者肝细胞癌的发生。
World J Clin Cases. 2023 Feb 16;11(5):1009-1018. doi: 10.12998/wjcc.v11.i5.1009.
5
A hierarchical multilabel graph attention network method to predict the deterioration paths of chronic hepatitis B patients.一种用于预测慢性乙型肝炎患者恶化路径的分层多标签图注意网络方法。
J Am Med Inform Assoc. 2023 Apr 19;30(5):846-858. doi: 10.1093/jamia/ocad008.
6
Influence of hepatitis B virus on the prevalence of diabetes complications in patients with type 2 diabetes.乙型肝炎病毒对 2 型糖尿病患者糖尿病并发症患病率的影响。
J Diabetes Investig. 2023 Mar;14(3):429-434. doi: 10.1111/jdi.13954. Epub 2022 Dec 12.
7
Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure.代谢风险因素与乙型肝炎病毒相关慢加急性肝衰竭的疾病严重程度和预后相关。
Gut Liver. 2022 May 15;16(3):456-464. doi: 10.5009/gnl210449.
8
Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg).乙肝病毒感染患者中的肝细胞癌及乙肝表面抗原(HBsAg)的作用
J Clin Med. 2022 Feb 21;11(4):1126. doi: 10.3390/jcm11041126.
9
The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments.脂肪变性对慢性丙型肝炎进展及抗病毒治疗反应的影响
Biomedicines. 2021 Oct 17;9(10):1491. doi: 10.3390/biomedicines9101491.
10
[Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study].慢性乙型肝炎相关性肝硬化合并2型糖尿病患者肝细胞癌的风险分析:一项5年前瞻性队列研究
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Mar 25;41(3):313-318. doi: 10.12122/j.issn.1673-4254.2021.03.01.